Detection, Significance and Potential Utility of Circulating Tumor Cells in Clinical Practice in Breast Cancer (Review)

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Nov 4

PMID 39492933

Authors

Dominika Smickova Rusnakova

Ramadan Aziri

Peter Dubovan

Miroslav Jurik

Michal Mego

Daniel Pindak

Affiliations

Soon will be listed here.

Abstract

Although advances in diagnostic techniques, new therapeutic strategies and personalization of breast cancer (BC) care have improved the survival for a number of patients, BC remains a major cause of morbidity and mortality for women. The study of circulating tumor cells (CTCs) has significant potential in translational oncology since these cells represent promising biomarkers throughout the entire course of BC in patients. CTCs also have notable prognostic value in early BC as well as metastatic BC. Based on current knowledge, it seems that the dynamics of CTCs that change during therapy reflect therapy response, and CTCs could serve as a tool for risk stratification and real-time monitoring of treatment in patients with BC. The question of how to use this information in everyday clinical practice and how this information can guide or change therapy to affect the clinical outcome of patients with BC remains unanswered. The present review aims to discuss current completed and ongoing trials that have been designed to demonstrate the clinical significance of CTCs, offer insights into treatment efficacy and assess CTC utility, facilitating their implementation in the routine management of patients with BC.

References

Mego M, Mani S, Lee B, Li C, Evans K, Cohen E . Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer. 2011; 130(4):808-16. PMC: 3169728. DOI: 10.1002/ijc.26037. View

Smerage J, Barlow W, Hortobagyi G, Winer E, Leyland-Jones B, Srkalovic G . Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014; 32(31):3483-9. PMC: 4209100. DOI: 10.1200/JCO.2014.56.2561. View

Hou H, Warkiani M, Khoo B, Li Z, Soo R, Tan D . Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013; 3:1259. PMC: 3569917. DOI: 10.1038/srep01259. View

Hall C, Valad L, Lucci A . Circulating Tumor Cells in Breast Cancer Patients. Crit Rev Oncog. 2016; 21(1-2):125-39. DOI: 10.1615/CritRevOncog.2016016120. View

Luc R, Tortorella S, Ververis K, Karagiannis T . Lactate as an insidious metabolite due to the Warburg effect. Mol Biol Rep. 2015; 42(4):835-40. DOI: 10.1007/s11033-015-3859-9. View

Cristofanilli M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006; 33(3 Suppl 9):S9-14. DOI: 10.1053/j.seminoncol.2006.03.016. View

Larsson A, Jansson S, Bendahl P, Jorgensen C, Loman N, Graffman C . Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018; 20(1):48. PMC: 5994056. DOI: 10.1186/s13058-018-0976-0. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Mego M, De Giorgi U, Hsu L, Ueno N, Valero V, Jackson S . Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol. 2009; 20(11):1824-8. DOI: 10.1093/annonc/mdp207. View

10.

Nasiri R, Shamloo A, Ahadian S, Amirifar L, Akbari J, Goudie M . Microfluidic-Based Approaches in Targeted Cell/Particle Separation Based on Physical Properties: Fundamentals and Applications. Small. 2020; 16(29):e2000171. DOI: 10.1002/smll.202000171. View

11.

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M . Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008; 14(9):2593-600. DOI: 10.1158/1078-0432.CCR-07-4758. View

12.

Pantel K, Speicher M . The biology of circulating tumor cells. Oncogene. 2015; 35(10):1216-24. DOI: 10.1038/onc.2015.192. View

13.

Budd G, Cristofanilli M, Ellis M, Stopeck A, Borden E, Miller M . Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006; 12(21):6403-9. DOI: 10.1158/1078-0432.CCR-05-1769. View

14.

Talasaz A, Powell A, Huber D, Berbee J, Roh K, Yu W . Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A. 2009; 106(10):3970-5. PMC: 2645911. DOI: 10.1073/pnas.0813188106. View

15.

Muller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E . Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012; 14(4):R118. PMC: 3680931. DOI: 10.1186/bcr3243. View

16.

Gorges T, Stein A, Quidde J, Hauch S, Rock K, Riethdorf S . Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®. PLoS One. 2016; 11(5):e0155126. PMC: 4868337. DOI: 10.1371/journal.pone.0155126. View

17.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

18.

Lindstrom L, Karlsson E, Wilking U, Johansson U, Hartman J, Lidbrink E . Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30(21):2601-8. DOI: 10.1200/JCO.2011.37.2482. View

19.

Wittekind C, Neid M . Cancer invasion and metastasis. Oncology. 2005; 69 Suppl 1:14-6. DOI: 10.1159/000086626. View

20.

OShannessy D, Davis D, Anderes K, Somers E . Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha. Biomark Insights. 2016; 11:7-18. PMC: 4737520. DOI: 10.4137/BMI.S35075. View